Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-11-12
2010-06-22
Woodward, Cherie M (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07741282
ABSTRACT:
The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
REFERENCES:
patent: 5763223 (1998-06-01), Wiley et al.
patent: 6030945 (2000-02-01), Ashkenazi
patent: 6284236 (2001-09-01), Wiley et al.
patent: 6497869 (2002-12-01), Williams et al.
patent: 6541606 (2003-04-01), Margolin et al.
patent: 0 417 563 (1991-03-01), None
patent: 0 870 827 (1998-10-01), None
patent: S62-283932 (1987-12-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 97/25428 (1997-07-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/28426 (1998-07-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 98/35986 (1998-08-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/09165 (1999-02-01), None
patent: PCT/US 99/06673 (1999-03-01), None
patent: WO 99/11791 (1999-03-01), None
patent: PCT/US 99/01039 (1999-07-01), None
patent: PCT/US 00/15512 (2000-12-01), None
patent: PCT/US 00/17579 (2001-01-01), None
patent: WO 01/00832 (2001-01-01), None
patent: WO 01/24814 (2001-12-01), None
patent: WO 01/24814 (2001-12-01), None
patent: PCT/US 01/23691 (2002-02-01), None
patent: WO 03/029420 (2003-10-01), None
Hymowitz et al., Biochemistry Feb. 1, 2000 39(4):633-40.
Information Hyperlinked Over Proteins [IHOP], TNFSF10.
Meyer et al., Pharm Biotechnol. 2002;13:85-107, Abstract Only.
Hymowitz et al., Biochemistry, Jan. 4, 2000; 39:633-640.
Walczak et al., Nature Medicine, Feb. 1999; 5(2):157-163.
Ashkenazi et al., J Clin Invest, Jul. 1999; 104(2):155-162.
Craft et al., Clin Chem, Jan. 1988;34(1):44-8, Abstract Only.
Page et al., J Pharm Pharmacol, Jan. 2000;52(1):19-26, Abstract Only.
Gueffroy, Ed. Buffers: A guide for the preparation and use of buffers in biological systems. Behring Diagnostics. Hoechst Corporation. 1975, pp. 10-11.
Stamenkovic et al., “A B-Lymphocyte Activation Molecule Related to the Nerve Growth Factor Receptor and Induced by Cytokines in Carcinomasis . . .”EMBO Journal. 8(5):1403-1410 (1989).
Thomas and Hersey, “TNF-Related Apoptosis-Inducing Ligand (TRAIL) Induces Apoptosis in Fas Ligand-Resistant Melanoma Cells and Mediates CD4 T Cell Killing of Target Cells”J. Immunol. 161:2195-2200 (1998).
Upton et al., “Myxoma Virus Expresses a Secreted Protein with Homology to the Tumor Necrosis Factor Receptor Gene Family that Contributes to Viral Virulence.”Virology. 184:370-382 (1991).
Upton et al., “Tumorigenic Poxviruses: Genomic Organization and DNA Sequence of the Telomeric Region of the Shope Fibroma Virus Genome.”Virology. 160:20-30 (1987).
Walczak et al., “TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL.”EMBO Journal16 (17): 5386-5397 (1997).
Walczak et al., “Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo”Nature Med. 5:157-163 (1999).
Wiley et al., “Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis”Immunity3:673-682 (1995).
Wu et al., “KILLER/DR5 is a DNA Damage-Inducible p53-Regulated Death Receptor Gene.”Nature Genetics. 17:141-143 (1997).
Yu et al., “Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Androgen-independent Prostate Cancer Cells”Cancer Research60:2384-2389 (2000).
Cha et al., “2.8 A Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity”Immunity11:253-261 (1999).
EP 0909564 has been considered, but JP-10-182481 is in Japanese, no translation has been provided, and there is no readily ascertainable citation on JP-10-182481 of on EP 0909564 establishing their relationship. Without sufficient identifying information, EP 0909564 cannot be considered an English language translation of JP-10-182181.
Locksley et al., “The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology”Cell104:487-501 (Feb. 23, 2001).
Wallach, “TNF Ligand and TNF/NGF Receptor Families”Cytokine Reference, Academic Press pp. 377-411 (2000).
Cromwell et al., “Self-Association of Therapeutic Proteins”Misbehaving Proteins, Springer Science+Business Media, LLC pp. 313-330 (2006).
Armitage et al., “Molecular and Biological Characterization of a Murine Ligand for CD40.”Nature. 357 (6373):80-82 (1992).
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand”Journal of Clinical Investigation104(2):155-162 (1999).
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation”Cell73:431-445 (1993).
Bodmer et al., “Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL”Journal of Biological Chemistry275:20632-20637 (2000).
Brockhaus et al., “Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies.”Proc. Natl. Acad. Sci. USA87:3127-3131 (1990).
Browning et al., “Lymphotoxin β, A Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface”Cell72:847-856 (1993).
Chicheportiche et al., “TWEAK, A New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis.”Journal of Biological Chemistry272(51):32401-32410 (1997).
Chinnaiyan et al., “Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy”Proc. Natl. Acad. Sci. 97:1754-1759 (2000).
Darby and Creighton, “Disulfide Bonds in Protein Folding and Stability”Methods in Enzymology, B.A. Shirley, Totowa, NJ:Human Press Inc, Chapter 10, vol. 40:219-252 (1995).
Dealtry et al., “DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon-γ”European Journal of Immunology17:689-693 (1987).
Degli-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family”Journal of Experimental Medicine186(7):1165-1170 (1997).
Degli-Esposti et al., “The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”Immunity7:813-820 (1997).
Gazitt, Y., “TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells”Leukemia13:1817-1824 (1999).
Gliniak and Le, “Tumor Necrosis Factor-related Apoptosis-inducing Ligand's Antitumor Activity in Vivo Is Enhanced by the Chemoptherapeutic Agent CPT-11”Cancer Research59:6153-6158 (1999).
Goodwin et al., “Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor.”Mol. Cell. Bio.11:3020-3026 (1991).
Griffith et al., “Monocyte-mediated Tumoricidial Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL”Journal of Experimental Medicine189:1343-1353 (1999).
Gruss and Dower, “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas”Blood85:3378-3404 (1995).
Hahne et al., “April, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth.”Journal of Experimental Medicine188(6):1185-1190 (1998).
Hale et al., “Demonstration of in Vitro and in Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed inE. coli.” J. Cell. Biochem. (abstract only, suppl. 15F; P 424) p. 113 (1991).
Hohmann et al., “Two Different Cell Types Ha
Flores Heather
Lin Tanya P.
Matthews Timothy C.
Pai Roger
Shahrokh Zahra
Genentech Inc.
Marschang Diane L.
Woodward Cherie M
LandOfFree
ApO2 ligand/TRAIL formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ApO2 ligand/TRAIL formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ApO2 ligand/TRAIL formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195823